Corcept Therapeutics Incorporated
CORT
$33.30
-$0.21-0.63%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 202.13M | 207.64M | 194.43M | 157.21M | 181.89M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 202.13M | 207.64M | 194.43M | 157.21M | 181.89M |
| Cost of Revenue | 2.55M | 4.60M | 3.43M | 2.40M | 2.96M |
| Gross Profit | 199.58M | 203.04M | 191.00M | 154.81M | 178.93M |
| SG&A Expenses | 130.24M | 123.98M | 103.85M | 90.66M | 83.37M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 197.64M | 197.42M | 167.76M | 153.80M | 156.63M |
| Operating Income | 4.49M | 10.22M | 26.68M | 3.42M | 25.26M |
| Income Before Tax | 9.91M | 15.24M | 31.69M | 9.62M | 31.96M |
| Income Tax Expenses | -14.38M | -4.43M | -3.46M | -10.93M | 1.21M |
| Earnings from Continuing Operations | 24.29M | 19.67M | 35.15M | 20.55M | 30.75M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 24.29M | 19.67M | 35.15M | 20.55M | 30.75M |
| EBIT | 4.49M | 10.22M | 26.68M | 3.42M | 25.26M |
| EBITDA | 4.78M | 10.51M | 26.96M | 3.70M | 25.54M |
| EPS Basic | 0.23 | 0.19 | 0.33 | 0.19 | 0.29 |
| Normalized Basic EPS | 0.06 | 0.09 | 0.19 | 0.06 | 0.19 |
| EPS Diluted | 0.20 | 0.16 | 0.29 | 0.17 | 0.26 |
| Normalized Diluted EPS | 0.05 | 0.08 | 0.16 | 0.05 | 0.17 |
| Average Basic Shares Outstanding | 103.70M | 103.55M | 104.11M | 104.11M | 103.64M |
| Average Diluted Shares Outstanding | 119.86M | 119.44M | 120.49M | 119.82M | 118.46M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |